AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule ...

AN2 Therapeutics said it was planning to meet with the U.S. Food and Drug Administration to discuss a development path for epetraborole, a treatment of non-tuberculous mycobacterial lung disease. The ...

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...

AN2 Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS – ...

AN2 Therapeutics, Inc. ( (ANTX)) has shared an announcement. AN2 Therapeutics has promoted its Chief Legal Counsel, Joshua Eizen, to the roles of Chief Legal Officer and Chief Operating Officer, ...

The measures taken as a result of losing the deal include cutting staff, which would occur with immediate effect.

If ultimately fully funded, the MPC2SC Program will start by identifying 10 students at the community college during their ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AUSTIN, Texas and NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to ...

The company has also laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial ...